Presentation Title

Examining trends in hormone therapy use in relation to ovarian cancer incidence

Faculty Mentor

Dr. Alice Lee

Start Date

18-11-2017 2:15 PM

End Date

18-11-2017 3:15 PM

Location

BSC-Ursa Minor 119

Session

Poster 3

Type of Presentation

Poster

Subject Area

health_nutrition_clinical_science

Abstract

Ovarian cancer is one of the leading causes of female cancer death in the United States. However, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, there has been a steady decline in the incidence of ovarian cancer, particularly among women who are ages 50+ which is when most are postmenopausal. Because the literature suggests that menopausal hormone therapy (HT) is a risk factor for ovarian cancer, we would expect a decline in HT use as well. Therefore, the goal of this project is to analyze the trends in HT use using data from the National Health and Nutrition Examination Survey (NHANES), a program that obtains the health and nutritional status of adults and children in the United States. HT data from 1999 to 2014 were used in this project. Also, we only focused on women ages 50+ since HT is an exposure related to menopause. We found that prevalence of HT use decreased from 39.16% in 1999-2000 to 30.99% in 2013-2014. This decrease was also seen in both types of HT (estrogen therapy and estrogen-progestin therapy). Therefore, these results support our hypothesis that like ovarian cancer incidence, use of menopausal HT has also declined over time. However, it is important to note that this analysis only focused on HT and did not account for other risk and protective factors that can affect the development of ovarian cancer.

This document is currently not available here.

Share

COinS
 
Nov 18th, 2:15 PM Nov 18th, 3:15 PM

Examining trends in hormone therapy use in relation to ovarian cancer incidence

BSC-Ursa Minor 119

Ovarian cancer is one of the leading causes of female cancer death in the United States. However, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, there has been a steady decline in the incidence of ovarian cancer, particularly among women who are ages 50+ which is when most are postmenopausal. Because the literature suggests that menopausal hormone therapy (HT) is a risk factor for ovarian cancer, we would expect a decline in HT use as well. Therefore, the goal of this project is to analyze the trends in HT use using data from the National Health and Nutrition Examination Survey (NHANES), a program that obtains the health and nutritional status of adults and children in the United States. HT data from 1999 to 2014 were used in this project. Also, we only focused on women ages 50+ since HT is an exposure related to menopause. We found that prevalence of HT use decreased from 39.16% in 1999-2000 to 30.99% in 2013-2014. This decrease was also seen in both types of HT (estrogen therapy and estrogen-progestin therapy). Therefore, these results support our hypothesis that like ovarian cancer incidence, use of menopausal HT has also declined over time. However, it is important to note that this analysis only focused on HT and did not account for other risk and protective factors that can affect the development of ovarian cancer.